Photo by finnnyc from unsplash
BCL10 mutations in diffuse large B-cell lymphoma (DLBCL) fall into two classes, with both conferring BTK inhibitor resistance but only truncation mutations conferring MALT1 dependency, suggesting use of these mutation… Click to show full abstract
BCL10 mutations in diffuse large B-cell lymphoma (DLBCL) fall into two classes, with both conferring BTK inhibitor resistance but only truncation mutations conferring MALT1 dependency, suggesting use of these mutation classes as precision therapy biomarkers.
Keywords:
precision therapy;
mutations define;
bcl10 mutations
Journal Title: Cancer Discovery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Discovery
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!